Shared on 16 Sep 25
Fair value Increased 2k%The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00. What's in the News Biodesix announced a 1-for-20 stock split.
Shared on 24 Apr 25
Fair value Decreased 40%AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.3%.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 78%AnalystConsensusTarget has increased revenue growth from 18.8% to 24.5%, increased future PE multiple from 58.3x to 99.5x and increased shares outstanding growth rate from 0.0% to 0.1%.